Atomoxetine treatment may decrease striatal dopaminergic transporter availability after 8 weeks: pilot SPECT report of three cases

Attention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Akay, Aynur Pekcanlar, Kaya, Gamze Capa, Baykara, Burak, Demir, Yusuf, Özek, Handan, Alsen, Sevay, Eren, Mine Sencan, Emiroglu, Neslihan Inal, Ertay, Turkan, Ozturk, Yesim, Miral, Suha, Durak, Hatice, Tufan, Evren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657797/
https://www.ncbi.nlm.nih.gov/pubmed/26640376
http://dx.doi.org/10.2147/NDT.S87359
Descripción
Sumario:Attention deficit/hyperactivity disorder is one of the most common neurodevelopmental disorders. The pathophysiology is thought to involve noradrenaline and dopamine. The role of dopamine transporter (DAT) was evaluated in imaging studies using mostly dopamine reuptake inhibitors. Atomoxetine is a selective noradrenaline reuptake inhibitor. Here we report the results of a pilot study conducted to evaluate changes in striatal DAT after 8 weeks of atomoxetine treatment. Our results suggest that 8 weeks of atomoxetine treatment may change striatal DAT bioavailability as measured via SPECT but that change was not correlated with genotype or clinical improvement.

Ejemplares similares